• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Study: Growing concern over narcotic painkillers and their addiction risk

March 3, 2017 By Sarah Faulkner

Study: Growing concern over narcotic painkillers and their addiction riskMore than 50% of Americans have been prescribed narcotic painkillers, according to a Truven Health Analytics-NPR Health poll, and more than one third of respondents were concerned about painkillers’ addiction risk, effectiveness and side effects.

The concern towards prescription painkillers differed between those who have been prescribed narcotic pain-relievers and those who have not. Just over 35% of respondents who have been prescribed these drugs said they have concerns – a number that has held steady since 2011.

This trend didn’t hold true for people who haven’t been prescribed narcotic painkillers, according to the data. In 2011, nearly 30% of respondents who have not been prescribed the drugs said they were worried about potential addictive side effects. However, that number grew in 2016 to 46% of respondents.

The most cited reasons for respondents’ concerns were fear of addiction and side effects. For those who have been prescribed the painkillers, fear of side effects ranked higher than fear of addiction. The opposite was true for those who have not been prescribed the drugs by their doctor.

“This data shows that people are becoming more aware of risks associated with narcotic painkillers,” Ronald Ozminkowski, VP of cognitive analytics for the value-based care biz at IBM Watson Health, said in prepared remarks. “What’s most fascinating, however, is that consumer concerns about side effects, addiction and long-term impact associated with the drugs are most pronounced among those who have never been prescribed narcotic painkillers. That exposes an educational challenge caregivers will need to address when prescribing these drugs.”

The results from the survey included data from 3,000 participants surveyed from Nov. 1 to Nov. 15 last year. The researchers added that the margin of error for each survey year is +/- 1.8 percentage points.

Truven Health Analytics is a part of the IBM Watson Health business.

Filed Under: Featured, Pharmaceuticals, Research & Development Tagged With: IBM Watson Health

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS